Suppr超能文献

同时性与异时性骨转移结直肠癌患者的临床病理特征、治疗策略及预后差异

The Distinction of Clinicopathological Characteristics, Treatment Strategy and Outcome in Colorectal Cancer Patients With Synchronous vs. Metachronous Bone Metastasis.

作者信息

Ma Chen-Xi, Guan Xu, Wei Ran, Wang Song, Quan Ji-Chuan, Zhao Zhi-Xun, Chen Hai-Peng, Liu Zheng, Jiang Zheng, Wang Xi-Shan

机构信息

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Bejing, China.

Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

Front Oncol. 2020 Jun 19;10:974. doi: 10.3389/fonc.2020.00974. eCollection 2020.

Abstract

The impact of the timing of bone metastasis (BM) diagnosis on colorectal cancer (CRC) patients is unclear. Our study aimed to explore the differences in clinicopathological characteristics, treatments and prognosis between synchronous BM (SBM) and metachronous BM (MBM) from CRC. We retrospectively investigated clinical data of CRC patients with SBM or MBM from 2008 to 2017 at Chinese National Cancer Center. Cancer specific survival (CSS) after BM diagnosis was estimated using the Kaplan-Meier method. The multivariable COX regression model identified the prognostic factors of CSS. Finally, 63 CRC patients with SBM and 138 CRC patients with MBM were identified. Compared to SBM from CRC, MBM significantly was more involving multiple bone lesions (63.0 vs. 7.9%; < 0.001), and more frequently originated from rectal cancer (60.9 vs. 41.3%; = 0.033). The therapeutic strategies in SBM and MBM group were contrasted including systemic treatment, bisphosphonates, radiotherapy and metastasectomy for BM. 85.5% of patients in MBM group and 25.4% of patients in SBM group underwent primary tumor resection at initial diagnosis ( < 0.001). The median CSS was 11 months in both SBM and MBM group ( = 0.556), yet MBM patients developed from CRC in early AJCC stage presented obviously longer survival than those from advanced stage. Furthermore, patients could have improved CSS from primary tumor resection while there might be no survival benefit from targeted therapy in both SBM and MBM groups. Bisphosphonates was associated with a better CSS for patients with SBM, while radiotherapy for BM was related to a better CSS for patients with MBM. The CRC patients in SBM and MBM group represented different clinicopathological characteristics and treatment modalities, which affected the prognosis in different ways. Distinct consideration for CRC patients with SBM and MBM in clinical decision making is required.

摘要

骨转移(BM)诊断时机对结直肠癌(CRC)患者的影响尚不清楚。我们的研究旨在探讨结直肠癌同步骨转移(SBM)和异时性骨转移(MBM)在临床病理特征、治疗方法及预后方面的差异。我们回顾性调查了2008年至2017年在中国国家癌症中心就诊的SBM或MBM结直肠癌患者的临床资料。采用Kaplan-Meier法估计骨转移诊断后的癌症特异性生存期(CSS)。多变量COX回归模型确定了CSS的预后因素。最终,共纳入63例SBM结直肠癌患者和138例MBM结直肠癌患者。与结直肠癌SBM相比,MBM累及多个骨病变的比例显著更高(63.0%对7.9%;P<0.001),且更常起源于直肠癌(60.9%对41.3%;P = 0.033)。对比了SBM组和MBM组的治疗策略,包括针对BM的全身治疗、双膦酸盐治疗、放疗和转移灶切除术。MBM组85.5%的患者和SBM组25.4%的患者在初次诊断时接受了原发肿瘤切除(P<0.001)。SBM组和MBM组的CSS中位数均为11个月(P = 0.556),然而,美国癌症联合委员会(AJCC)早期阶段的结直肠癌MBM患者的生存期明显长于晚期患者。此外,两组患者行原发肿瘤切除均可改善CSS,但靶向治疗对SBM组和MBM组患者可能均无生存获益。双膦酸盐治疗与SBM患者较好的CSS相关,而针对BM的放疗与MBM患者较好的CSS相关。SBM组和MBM组的结直肠癌患者表现出不同的临床病理特征和治疗方式,对预后产生不同影响。在临床决策中,需要对SBM和MBM的结直肠癌患者进行不同的考量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a8c/7318073/80cf7fb78bae/fonc-10-00974-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验